Paragon 2 trial anzgog
Web129 The PARAGON (ANZGOG-0903) trial is an investigator-initiated basket trial 130 investigating the activity of anastrozole in post-menopausal patients with a wide 131 … WebBackground There is some evidence that a subset of patients with recurrent ovarian cancer may benefit from antiestrogen therapy. The Paragon study is a basket protocol that …
Paragon 2 trial anzgog
Did you know?
WebPARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. ... PARAGON is a basket trial that incorporates 7 phase 2 trials investigating the activity of anastrozole in patients with ER⁺ and/or progesterone receptor (PR ... WebMay 23, 2024 · PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
WebFeb 16, 2024 · 2. Materials and methods PARAGON is a Gynecologic Cancer InterGroup trial led by the Australian New Zealand Gynecological Oncology Group (ANZGOG) and coordinated by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney. WebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor–positive recurrent gynecological cancers. ... Median progression-free survival was 2.7 months (95% CI, 2.0–2.8 months). The median duration of clinical benefit was 2.8 ...
WebPARAGON is a basket trial that incorporates 7 phase 2 trials investigating the activity of anastrozole in patients with ER+ and/or progesterone receptor (PR)-positive (PR+) recurrent/metastatic gynecological cancers. Methods Postmenopausal women with ER+ and/or PR+ ROC, who were asymptomatic and had cancer antigen 125 (CA125) … WebOct 24, 2015 · PARAGON- an ANZGOG Phase 2 study of anastrazole in asymptomatic women with estrogen (ER)/progesterone (PR) positive ovarian cancer with GCIG CA125 progression after first line treatment....
WebJul 1, 2024 · Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903 - ScienceDirect …
WebMay 23, 2024 · The PARAGON (ANZGOG-0903) trial is an investigator-initiated basket trial investigating the activity of anastrozole in post-menopausal patients with a wide range of ER or PR positive recurrent or metastatic gynaecological tumours. calhounc2 upmc.eduWebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor-positive … coachman camper dealer near mecalhoun bros body shopWebMay 20, 2016 · 5520 Background: Many endometrial cancers express hormone receptors and may respond to hormonal therapy, but the impact on quality of life (QOL) is unclear. The aim of PARAGON is to investigate anastrozole, in patients (pts) with various ER/PR positive metastatic gynaecological cancers in a series of 7 individual phase 2 studies embedded … calhoun brothers singersWebSep 1, 2024 · PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression Project:... coachman camperWebApr 1, 2024 · 2. Materials and methods PARAGON is a Gynecologic Cancer InterGroup trial led by the Australian New Zealand Gynecological Oncology Group (ANZGOG) and coordinated by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney. coachman camper reviewsWebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor–positive … calhoun building systems